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Abstract Mitogen-activated protein kinase (MAPK) pathways
transfer environmental signals into intracellular events such as
proliferation and di¡erentiation. Fungi utilize a speci¢c phero-
mone-induced MAPK pathway to regulate conjugation, forma-
tion of an ascus, and entry into meiosis. We have previously
identi¢ed a MAPK, PCM, from the fungal opportunist Pneu-
mocystis, responsible for causing severe pneumonia in patients
with AIDS. In order to gain insight into the function of PCM,
we expressed it in Saccharomyces cerevisiae de¢cient in pher-
omone signaling and tested activation and inhibition of this
MAPK pathway. PCM restored pheromone signaling in S. ce-
revisiae fus3v kss1v mutants with K-factor pheromone (six-fold
increase) and was not activated by osmotic stress. Signaling
through this pathway decreased 2.5-fold with 10 WM U0126,
and was una¡ected with SB203580. We evaluated the conditions
for native PCM kinase activity isolated from Pneumocystis ca-
rinii organisms and found that 0.1 mM MgCl2, pH 6.5, temper-
ature 30^35‡C, and 10 WM ATP were optimal. The activity of
PCM is signi¢cantly elevated in P. carinii trophic forms com-
pared to cysts, implicating a role for PCM in the life cycle
transition of P. carinii from trophic forms to cysts.
8 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Mitogen-activated protein kinase (MAPK) signal transduc-
tion cascades are used by fungi to regulate cellular responses
for mating, environmental stress, and cell wall integrity [1,2].
The ascomycetous yeast Saccharomyces cerevisiae activates a
MAPK pathway for mating upon exposure to pheromones,
which results in the conjugation of yeast cells. Subsequent
events include the formation of an ascus and entry into meio-
sis [3^7]. Pneumocystis, a fungal opportunist grouped phylo-
genetically within the ascomycetous yeasts, is responsible for
causing severe pneumonia in patients infected with the human
immunode¢ciency virus. Patients receiving chronic immuno-
suppression or those with other immune system impairments
are also at high risk for infection [8^11]. Pneumocystis carinii
has two life cycle stages which are identi¢able by light micros-
copy, the trophic form and the cyst [12^18]. Unfortunately, it
is not possible to culture P. carinii outside the infected host
[19]. Further, methods for gene transfer or disruption are not
available for P. carinii. Therefore the mechanisms regulating
life cycle events, such as the transition from trophic forms to
cysts, are unknown.
The pheromone-induced MAPK pathway has been exten-
sively studied in S. cerevisiae, where haploid cells conjugate
after the secretion of peptide mating pheromones. A hetero-
trimeric G protein coupled to the pheromone receptor prop-
agates the mating signal to a module of serine-threonine pro-
tein kinases, MEKK, MEK, and MAPK, each of which
becomes activated by sequential phosphorylation. Activated
MAPK induces a controlled exit from the mitotic cell cycle
to allow cellular synchronization prior to meiosis, and the
expression of a number of molecules required for meiosis
and formation of the ascus [3^5,20]. In some pathogenic fun-
gi, this same MAPK pathway regulates mating but also has
additional roles in regulating fungal virulence [21^23]. MAPK
molecules from Giardia have recently been shown to be im-
portant regulators of life cycle transition within these para-
sites. The Giardia MAPKs control the encystation of troph-
ozoites under poor nutrient conditions, which is similar to the
signals which activate this pathway in S. cerevisiae to prompt
pheromone release [24].
We have previously cloned a MAPK from P. carinii, PCM,
which has signi¢cant sequence homology to S. cerevisiae
FUS3 [25]. Here we report that expression of PCM in S. ce-
revisiae complements pheromone signaling in these yeast, and
that this response can be inhibited by U0126, which is known
to block MEK activation of MAPK. PCM isolated from
P. carinii directly from infected lungs reveals unique require-
ments of pH, temperature, and divalent cation concentration
for optimal kinase activity. We investigated PCM mRNA ex-
pression and kinase activity in P. carinii trophic forms and
cysts, and the elevated kinase levels present in trophic forms
suggest that PCM may have a role in regulating the transition
of trophic forms into cysts.
2. Materials and methods
2.1. Materials
S. cerevisiae K-factor pheromone and all chemical reagents were
purchased from Sigma Chemical (St. Louis, MO, USA). S. cerevisiae
K-factor pheromone was dissolved in sterile water to produce a stock
solution of 1 mg/ml. Restriction endonucleases, Taq polymerase, Super-
script II RT, and RNase-free DNase I were from Invitrogen. PHAS-I
(phosphorylated heat- and acid-stable protein) was from Stratagene.
[Q-32P]ATP was obtained from ICN Pharmaceuticals. U0126 and the
p38 inhibitor SB203580 were obtained from Promega. U0126 and
SB20358 were dissolved in dimethyl sulfoxide (DMSO) to produce
stock solutions of 10 mM. Fluorescein di-L-D-galactopyranoside
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(FDG) was obtained from Molecular Probes and made as a 10 mM
stock solution in DMSO. The pT-E-pY antibody which detects dually
phosphorylated MAPK was obtained from Sigma.
2.2. Yeast strains, plasmids, and transformation
S. cerevisiae EY2516 (MATa sst1v ade2-1 hisv200 leu2-3,112 trp1-1
ura3-1 can1-100 fus3-6: :LEU2 kss1: :HIS3 lys2: :FUS1-lacZ Gal+)
used in this study was a generous gift from Dr. Elaine Elion, Harvard
Medical School [26]. The S. cerevisiae expression plasmid p426GPD
(ATCC) containing the URA3 auxotrophic marker was used to ex-
press PCM (GenBank accession AF043941) under the constitutive
GPD promoter [27]. The plasmid p426GPD-PCM was constructed
as follows: PCM cDNA previously cloned into the plasmid pBlue-
script SK3 was ampli¢ed by polymerase chain reaction (PCR) using
the 5P EcoRI primer: GAATTCATGACAGCTTCAAGTAGA and
the 3P XhoI primer: CTCGAGTCAATTGTTCATACTCATAAT
with Pfx polymerase [25]. The PCR product was digested with EcoRI
and XhoI, directionally cloned into p426GPD, and was sequenced
completely to con¢rm that no PCR errors were introduced. S. cere-
visiae FUS3 was expressed from the plasmid pYES2.1-GS (Invitro-
gen). EY2516 yeast were grown overnight in YEPD medium at 30‡C
to an OD600 of 1.0 and were electroporated with the plasmids
p426GPD-PCM or pYES2.1-SCFUS3 as previously described [28].
Following electroporation, transformants were grown on glucose min-
imal medium lacking uracil at 30‡C.
2.3. Fus1-lacZ assays
PCM complementation of pheromone-induced signaling was tested
by measurement of the L-galactosidase reporter gene Fus1-lacZ in
EY2516 using FDG as a substrate [29]. EY2516 yeast transformed
with p426GPD-PCM or pYES2.1-SCFUS3 were grown in glucose
liquid minimal medium lacking uracil at 30‡C for 24 h. After an
overnight growth, cultures were diluted to an OD600 of 0.1 in glucose
(p426GPD-PCM) or galactose (pYES2.1-SCFUS3) minimal medium
lacking uracil and grown to an OD600 of 0.3. Triplicate cultures were
aliquoted into 96 well ‘U’ bottom micro£uor plates (ThermoLabsys-
tems). Cultures received U0126 (0^100 WM) or SB203580 (0^100 WM)
for 30 min (¢nal DMSO concentration for all dilutions was 1%), then
K-factor pheromone (¢nal concentration 10 WM) for 30 min. Addi-
tional control cultures received vehicle alone (1% DMSO), 500 mM
NaCl, or 10 WM K-factor pheromone for 30 min. Total volume of all
wells was 100 Wl. FDG substrate solution was prepared by diluting the
10 mM FDG stock solution to 1 mM in 25 mM PIPES, pH 7.2, and
mixing equal parts of this with 5% Triton X-100 in 250 mM PIPES
(pH 7.2). 20 Wl of the FDG substrate solution was aliquoted into each
well and the plate was incubated in the dark for 60 min at 37‡C. The
£uorescent signal was read in a Fusion 3.5 multiplate £uormeter with
an excitation ¢lter of 485 and an emission ¢lter of 530. In order to
determine if the observed reduction in Fus1-lacZ activity with U0126
was due to yeast death, S. cerevisiae expressing PCM received 0^100
WM of U0126 for 1, 3, 7 or 24 h. Dilutions of control yeast and test
yeast at each time point were plated in triplicate and colonies were
counted.
2.4. Preparation of P. carinii organisms
All studies described in this report were approved by the institu-
tional animal care and use committee (IACUC). P. carinii pneumonia
was induced in Harlan Sprague^Dawley rats by immunosuppression
with dexamethasone as previously reported [25,28,30,31]. Lungs from
moribund rats were minced and homogenized in Hanks’ balanced salt
solution and P. carinii were puri¢ed from host lung cells by ¢ltration
through a 10 Wm ¢lter (Millipore). P. carinii organisms were con-
¢rmed by Wright-Giemsa staining and samples containing contami-
nating bacterial or fungal organisms were discarded. Separated life
forms of P. carinii cysts and trophic forms were puri¢ed by di¡erential
¢ltration using 3 Wm Nuclepore ¢lters (which retain the cysts). The
trophic forms are collected by centrifugation. The cysts are collected
by washing and vortexing the 3 Wm ¢lter vigorously followed by
centrifugation. To verify the purity of the separated trophic and
cyst forms, we counted duplicate microscopy slides of each life
form-enriched fraction which were stained with GMS or Di¡-Quik.
2.5. Northern analysis
Total RNA was isolated from separated P. carinii trophic forms
and cysts with Trizol reagent (Invitrogen), and 10 Wg were separated
on 1.0% formaldehyde-agarose gels [31^33]. RNA was transferred to
Nytran Plus membranes (Schleicher and Schuell), and hybridization
to the radiolabeled PCM probe was performed at 68‡C using Express
hybridization solution (Clontech). Following exposure to autoradiog-
raphy ¢lm, the membranes were re-probed using a radiolabeled
P. carinii actin probe.
2.6. Quantitative reverse transcription (RT)-PCR
Total RNA was isolated from separated P. carinii trophic forms
and cysts with Trizol reagent (Invitrogen) as described above. 2 Wg of
total RNA from trophic forms and cysts was treated with RNase-free
DNase I and cDNA was synthesized from these samples by priming
with oligo(dT)18 using the Superscript II RT. The PCR primers 5PCM
(5P-CTTGGCACGATCTGCTGTTA-3P) and 3PCM (5P-GCTCTGC-
GAGACTTGATTCC-3P) amplify a 273 bp product of the PCM
cDNA. A competitor mimic cDNA was prepared by PCR by ampli-
fying a truncated portion of the target gene using the hybrid primer
5PCM1 (5P-CTTGGCACGATCTGCTGTTACTTCAAAGAATAC-
ACC-3P, which contains the 5PCM primer sequence and a down-
stream PCM sequence), and 3PCM. The resulting 197 bp PCR am-
plicon was subcloned into the pGEM-T Easy plasmid (Promega),
propagated in Escherichia coli DH5K, and the plasmids puri¢ed
with the QIAprep spin miniprep kit (Qiagen). The mimic cDNA
was released from the plasmid by restriction endonuclease digestion
with EcoRI, gel-puri¢ed using Geneclean spin (Bio 101), and quanti-
¢ed using a spectrophotometer. The mimic cDNA was initially diluted
10-fold ranging from 1 pmol/Wl to 1 amol/Wl and co-ampli¢ed with a
constant amount of the trophic form or cyst cDNA sample in a 50 Wl
reaction that included 1UPCR bu¡er, 50 WM dNTPs, 0.4 WM each of
the primers 5PCM and 3PCM, and 1.25 units of Taq polymerase.
Samples were ampli¢ed for 35 cycles at 94‡C for 30 s, 52‡C for 30 s,
and 72‡C for 30 s, and the PCR products were subjected to electro-
phoresis on 2% agarose gels. After the initial screening using 10-fold
serially diluted competitor mimic cDNA, the optimal range of com-
petitor mimic cDNA used to quantify PCM was two-fold dilutions
starting from 1U10317/Wl to 6.25U10319/Wl. The images were digitized
and the intensities of bands in ethidium bromide-stained gels quanti-
¢ed using the public domain NIH Image program (developed at the
US National Institutes of Health and available on the Internet at
http://rsb.info.nih.gov/nih-image/) and the ratio of PCM to mimic
cDNA was plotted against the competitor numbers. Using linear
regression, the equivalence point (log ratio= 0) was determined for
the samples of trophic forms and cysts and reported as the number
of copies of PCM/Wg total RNA.
2.7. Immunoprecipitation kinase assays and Western blotting
A PCM antiserum was prepared by Bethyl Laboratories (Mont-
gomery, TX, USA) by immunizing two rabbits with a peptide derived
from the N-terminal PCM sequence (MTASSRNVRFNVSDD, resi-
dues 1^15) coupled to keyhole limpet hemocyanin [25]. The IgG frac-
tion was puri¢ed from the antiserum using a protein A-Sepharose
column, and tested by enzyme-linked immunosorbent assay (ELISA)
against the cognate antigen to determine the optimal antibody titer
compared to non-immune rabbit IgG. PCM peptide was coated on
microtiter wells, reacted with dilutions of antibody, then with goat
anti-rabbit IgG(hpl)/horseradish peroxidase, followed by TMB/H2O2
substrate. A PCM antibody dilution of 1:20 000 produced an OD of
1.0 in the ELISA with no reactivity with the non-immune antibody. A
PCM antibody dilution of 1:10 000 was used for immunoprecipitation
and Western blotting. EY2516 yeast transformed with p426GPD-
PCM were grown in glucose minimal medium to an OD600 of 0.3.
One half of the culture received K-factor pheromone (10 WM ¢nal
concentration). Cultures were incubated for 30 min at 30‡C, then cells
were pelleted, washed in sterile water, and lysed in YPER reagent
(Pierce) containing a protease/phosphatase inhibitor cocktail (1 Wg/
ml each of leupeptin, aprotinin, and pepstatin; 1 mM each of phen-
ylmethylsulfonyl £uoride and sodium orthovanadate; and 50 mM
sodium £uoride) for 20 min at room temperature. The protein con-
centration of the lysates was determined spectrophotometrically using
the BCA method (Pierce) and equal protein (25 Wg) was boiled in
Laemmli bu¡er, separated by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE), and transferred to nitrocellulose
membranes. The membranes were incubated with the pT-E-pY anti-
bodies (1:1000), or PCM antibodies (1:10 000) for 2 h. Immunoreac-
tive bands were visualized by enhanced chemiluminescence (Amer-
sham Pharmacia Biotech) following the procedures recommended by
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the manufacturer. Puri¢ed P. carinii organisms were lysed in YPER
reagent (Pierce) as above. Protein lysate (500 Wg) was precleared with
a 50% slurry of protein A-Sepharose at 4‡C for 30 min, and PCM was
immunoprecipitated at 4‡C for 2 h using 1:10 000 dilution of PCM
antibody. The immunocomplexes were captured with protein A-Se-
pharose and were washed twice in wash bu¡er (50 mM Tris^HCl,
pH 7.5, 100 mM NaCl, 50 mM NaF, 1% Triton X-100, 1 mM
EDTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl
£uoride, 1 Wg/ml each of leupeptin, aprotinin, and pepstatin, and 25
mM L-glycerolphosphate) and twice in kinase bu¡er (50 mM HEPES
pH 7.5, 1 mM dithiothreitol). The immunocomplexes were added to a
40 Wl reaction containing 50 mM HEPES. We tested pH 6^9, MgCl2
concentrations of 0^30 mM, PHAS-I substrate from 0 to 14 Wg, and
cold ATP from 5 to 200 WM. Each reaction was started by the addi-
tion of 10 WCi [Q-32P]ATP and incubation in a shaking water bath for
30 min at temperatures ranging from 5 to 50‡C. Kinase reactions were
stopped with the addition of Laemmli bu¡er, boiled for 5 min, re-
solved by electrophoresis on 12% SDS^polyacrylamide gels, and sub-
jected to autoradiography [25]. All kinase reactions were performed in
triplicate from separate isolates of P. carinii organisms.
3. Results
3.1. P. carinii PCM complements pheromone signaling in yeast
We have previously shown that P. carinii PCM has 64%
identity to the pheromone-induced MAPK FUS3 from S. ce-
revisiae [25]. In order to determine if PCM is a functional
kinase in S. cerevisiae, we used PCM to complement S. cere-
visiae fus3v kss1v yeast treated with K-factor pheromone or
salt. These yeast have a Fus1-lacZ reporter gene incorporated
into their genome which is speci¢cally activated upon expo-
sure to K-factor pheromone if the pheromone-induced MAPK
cascade is functional [26]. As shown in Fig. 1, PCM expressed
in these yeast have a six-fold induction of Fus1-lacZ activity
with K-factor pheromone, similar to the control yeast express-
ing wild-type FUS3. Fus1-lacZ induction is minimal in yeast
given the vehicle control with 1% DMSO (designated 3) or
500 mM NaCl. Speci¢city of the pheromone induction in
Fig. 1. P. carinii PCM complements pheromone signaling in yeast. S. cerevisiae EY2516 (fus3v kss1v) yeast transformed with either PCM or
SCFUS3 were assayed for Fus1-lacZ activity in the presence of 10 WM K-factor, 500 mM salt, or the inhibitors U0126 and SB203580 (0^100
WM). Untreated yeast (3) received 1% DMSO as a vehicle control. Triplicate cultures were tested for each condition. LacZ units were calcu-
lated from the £uorescent intensity normalized for cell density and the mean of three individual experimentsW S.D. is shown.
Fig. 2. P. carinii PCM kinase activity in yeast. PCM was immuno-
precipitated from S. cerevisiae EY2516 (fus3v kss1v) yeast with and
without exposure to K-factor and PCM activity was investigated
by immunoblotting with a phosphoantibody to detect the dually
phosphorylated motif pT-E-pY and by performing in vitro kinase
assays.
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yeast expressing PCM with and without exposure to K-factor
pheromone was veri¢ed by performing immunoprecipitation
kinase reactions and immunoblotting (Fig. 2) using the phos-
phospeci¢c antibody which detects the dually phosphorylated
MAPK motif pT-E-pY, which is present in PCM and has
been used previously to detect activated S. cerevisiae FUS3
[25,34].
3.2. U0126 inhibits pheromone-induced signaling in yeast
We attempted to decrease the observed K-factor pheromone
induction in these yeast expressing PCM or wild-type FUS3
using inhibitors of MAPK signaling, U0126 and SB203580.
U0126 inhibits the upstream kinases MEK1 and MEK2,
thereby preventing activation of MAPK [35,36]. U0126 inhib-
its the mammalian extracellular signal-regulated kinase (ERK)
pathway, which has closest homology to the pheromone-in-
duced MAPK pathway in fungi. SB203580 is a speci¢c inhib-
itor of the p38 HOG pathway and interacts directly with the
active site in p38 to prevent its kinase activity. U0126 inhibits
MEK1 and MEK2 with an IC50 of 0.5 WM in vitro, but
e¡ective in vivo doses range from 10 to 100 WM [35,36].
SB203580 is a speci¢c inhibitor of the p38 HOG MAP kinase
with an IC50 of 1.0 WM in vitro, and e¡ective in vivo doses
ranging from 1 to 10 WM [37^39]. As shown in Fig. 1, U0126
reduces Fus1-lacZ activity of S. cerevisiae fus3v kss1v yeast
expressing PCM or FUS3 when treated for 30 min prior to
induction with K-factor pheromone in a dose-dependent man-
ner. Yeast expressing PCM had a reduction of 1.09-fold with
Fig. 3. PCM mRNA expression in trophic forms and cysts. P. cari-
nii PCM mRNA expression was determined by Northern blotting
using 10 Wg of total RNA from separated trophic forms (T)
and cysts (C). Hybridization was with PCM and P. carinii actin
probes.
Fig. 4. PCM kinase activity in trophic forms and cysts. PCM was
immunoprecipitated from P. carinii from infected rat lung using the
speci¢c PCM antibody (1:10 000 dilution) and tested in kinase as-
says. PCM activity is greatly augmented in trophic forms compared
to cysts, with equal protein detection of PCM in both trophic forms
and cysts. IgG heavy chains are indicated by the upper arrow. Con-
trol reactions using a non-immune antibody (1:10 000) does not
demonstrate any signi¢cant kinase activity.
Fig. 5. Metal dependence of native PCM kinase. PCM was immu-
noprecipitated from P. carinii from infected rat lung and tested in
kinase assays with various divalent cations (1 mM each). As shown
in the upper panel, Mg2þ followed by Mn2þ are preferred cations
for PCM. Next, the optimal concentration of Mg2þ was found to
be 0.1 mM (middle panel). Concentrations above 10 mM inhibited
kinase activity (lower panel).
Table 1
Purity of separated P. carinii life cycle forms
Trophic form-enriched fraction













Whole P. carinii organisms are separated from host lung cells by ¢l-
tration through a 10 Wm ¢lter. Trophic forms are separated from
cysts by further ¢ltration through a 3 Wm Nuclepore ¢lter (which re-
tains the cysts). The trophic forms are collected by centrifugation.
The cysts are collected by washing and vortexing the 3 Wm ¢lter vig-
orously followed by centrifugation. We counted duplicate microsco-
py slides of each enriched fraction which were stained with GMS
and Di¡-Quik. Di¡erential ¢ltration yielded a trophic form fraction
remarkably free from cysts, and cystic fractions were signi¢cantly
enriched in thick-walled cyst forms of the organism. The trophic
form fraction was greater than 99.99% pure trophic forms. The cyst
fraction contained 92.6% cysts on a per organism basis.
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1 WM U0126, 2.5-fold with 10 WM U0126, and 2.6-fold with
100 WM U0126. Yeast expressing FUS3 had a reduction of
1.9-fold with 1 WM U0126, 2.5-fold with 10 WM, and 3.4-fold
with 100 WM U0126. Yeast cultures expressing PCM or FUS3
had no signi¢cant reduction in Fus1-lacZ activity with the p38
inhibitor SB203580 in the range of 0.1^10 WM, however the
yeast expressing PCM had a 1.7-fold reduction with 100 WM
of SB203580 (Fig. 1). This dose of SB203580 is much higher
than what is normally used for speci¢c inhibition of p38 and
the small observed reduction in Fus1-lacZ activity might rep-
resent non-speci¢c inhibition of PCM. Since U0126 reduced
Fus1-lacZ activity in these yeast, we grew these yeast express-
ing PCM for 24 h in 0^100 WM of U0126 and counted trip-
licate dilutions of treated and untreated colonies to determine
if U0126 was causing cellular death of these yeast. S. cerevi-
siae expressing PCM and treated with U0126 had no reduc-
tion in colony-forming units; thus U0126 appears to speci¢-
cally inhibit MAPK signaling without resulting in death of the
yeast.
3.3. P. carinii trophic forms exhibit increased PCM kinase
activity
Since MAPK molecules can be di¡erentially regulated in
certain life cycle stages of pathogenic fungi or protozoans,
we sought to determine if the expression level and kinase
activity of PCM was predominant in a single life cycle form
of P. carinii. This may indicate that a single life cycle form
uses this MAPK signaling pathway to regulate the transition
from one life cycle form to another. First, we separated tro-
phic forms and cysts and veri¢ed the purity of these popula-
Fig. 6. Optimal pH and temperature for native PCM kinase activity. PCM was immunoprecipitated from P. carinii from infected rat lung and
tested in kinase assays with MgCl2 (0.1 mM) at pH 6^9 and at 5^50‡C. As shown in the upper panel, pH 6.5 appears optimal for PCM kinase
activity. In the lower panel, a temperature between 30 and 35‡C is optimal for PCM kinase activity.
FEBS 27602 27-8-03
P.K. Vohra et al./FEBS Letters 551 (2003) 139^146 143
tions. As shown in Table 1, trophic forms and cyst prepara-
tions were signi¢cantly enriched with little cross-contamina-
tion. These separated populations were used for PCM mRNA
expression and kinase activity. Northern analysis using a ra-
diolabeled PCM probe revealed that the level of expression of
the PCM mRNA in both trophic forms and cysts was low
compared to the actin gene (Fig. 3). We also evaluated PCM
mRNA expression by competitive RT-PCR using a mimic
system, where PCM expression by competitive RT-PCR was
slightly increased in trophic forms (3.2U10318 copies/Wg
RNA) compared to cysts (1U10318 copies/Wg RNA). PCM
kinase activity from cellular lysates of puri¢ed trophic forms
and cysts (500 Wg each) was examined by immunoprecipita-
tion kinase assay. PCM kinase activity from trophic forms is
signi¢cantly increased compared to cysts (Fig. 4). Control im-
munoprecipitation experiments on these same samples of tro-
phic forms and cysts using a non-immune antibody (1:10 000
dilution, same as that used for the PCM antibody) show min-
imal kinase activity, con¢rming that the observed kinase ac-
tivity is derived from PCM. Western blotting with PCM in
both samples reveals equal PCM protein was immunoprecipi-
tated from trophic forms and cysts. These data indicate that
PCM is activated in P. carinii trophic forms, and that the
increased activity is not due to di¡erences in the amount of
PCM protein immunoprecipitated from trophic forms and
cysts.
Fig. 7. E¡ect of ATP and substrate concentration on native PCM kinase activity. PCM in vitro kinase assays were performed as described
with MgCl2 (0.1 mM) at pH 6.5 and 35‡C testing a range of ATP as a phosphate donor (upper panel) or PHAS-I as a substrate (lower panel).
As shown, 10 WM ATP and 2^4 Wg PHAS-I are optimal for PCM kinase activity.
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3.4. Characterization of PCM kinase activity
For partial biochemical characterization of PCM, we iso-
lated native PCM from P. carinii by immunoprecipitation and
performed in vitro kinase assays using PHAS-I as a phosphor-
ylation substrate in the presence of [Q-32P]ATP. Metal depen-
dence with divalent cations for PCM activity was greatest
with magnesium chloride followed by manganese chloride,
while calcium chloride, copper chloride, and nickel chloride
demonstrated minimal kinase activity (Fig. 5). Use of cobalt
chloride in the reaction abolished kinase activity. Next, we
tested a range of magnesium chloride concentrations for ki-
nase activity and found 0.1 mM was optimal (Fig. 5). PCM
kinase activity was signi¢cantly reduced with 10 mM or higher
concentrations of magnesium chloride. We discovered that
optimal PCM kinase activity occurred under acidic conditions
at pH 6.5 (Fig. 6) and at elevated temperature (30^35‡C). This
is intriguing, since these conditions occur physiologically in
the host during pneumonia. The optimal concentration of
ATP as a phosphate donor is 10 WM, and the optimal con-
centration of PHAS-I substrate is between 2 and 4 Wg (Fig. 7).
4. Discussion
Insight into the life cycle of P. carinii has come from mi-
croscopic analysis of organisms obtained from the lungs of
infected animals or humans. The major limitation to a de-
tailed analysis of the P. carinii life cycle has been the inability
to culture and propagate P. carinii outside the lung. Because
of this limitation, our accumulated knowledge of the P. carinii
life cycle comes from observational studies. By light micros-
copy one can identify the small trophic forms (one Wm) and
the larger cysts (8 Wm) [16^18]. We and others have demon-
strated that the trophic forms are predominately haploid, but
also exist in diploid forms, and that the cyst have comple-
ments of 2, 4 or 8 nuclei [40,41]. We hypothesize that the
trophic forms use a MAPK signal transduction cascade to
control the transition into cysts. In the present investigation
we examine the function of P. carinii PCM in a heterologous
fungal system and perform partial biochemical characteriza-
tion of native PCM from P. carinii. We also investigate the
expression and activity of PCM in separated populations of
trophic forms and cysts in order to gain insight into the
P. carinii life cycle.
Our experimental data show that PCM can functionally
complement pheromone signaling in S. cerevisiae. PCM was
able to restore pheromone signaling in these yeast to identical
levels of the wild-type FUS3. Further, PCM is speci¢c for the
S. cerevisiae pheromone pathway, since induction occurred
only with K-factor pheromone. There was no induction with
500 mM NaCl as an osmotic stress, nor any reduction using
the p38 HOG inhibitor SB203580 in physiologically relevant
doses. The upstream kinase MEK phosphorylates ERK and
fungal pheromone-induced MAPKs on the threonine and ty-
rosine amino acids in the activation domain, and both phos-
phorylations are required for functional kinase activity [6].
ERK and fungal pheromone-induced MAPK molecules have
a T-E-Y motif in the activation domain of the kinase, which is
present in S. cerevisiae FUS3 and P. carinii PCM [25,34].
MAPKs which function in response to osmolar stress have
T-G-Y in the activation domain, and cell wall integrity
MAPKs have T-P-Y. Treatment of S. cerevisiae expressing
PCM or FUS3 with U0126 prior to K-factor pheromone ex-
posure signi¢cantly reduced Fus1-lacZ activity in a dose-de-
pendent manner. Activated PCM was detected in yeast treated
with K-factor pheromone both by immunoprecipitation kinase
reactions and by using a MAPK phosphorylation-speci¢c
antibody which detects the dual phosphorylations on the mo-
tif pT-E-pY, con¢rming activation of PCM within the yeast
pheromone-induced MAPK pathway.
MAPK molecules such as ERK and FUS3 have speci¢c
biochemical requirements for functional kinase activity.
MAPKs utilize a divalent cation, usually Mg2þ, as a necessary
co-factor for activity. The kinases also require ATP as a phos-
phate donor, and have an optimal range for temperature and
pH to function properly. We investigated these properties of
PCM isolated from P. carinii organisms during active infec-
tion. Similar to other MAPKs, PCM preferred Mg2þ, fol-
lowed by Mn2þ, as the divalent cation. Interestingly, a lower
than expected concentration of Mg2þ was optimal, 0.1 mM,
which is much less than other MAPKs. Concentrations of
Mg2þ above 10 mM inhibited kinase activity. PCM activity
was maximal with 10 WM ATP as a phosphate donor and 2^4
Wg of PHAS-I substrate. We also found PCM prefers pH 6.5
and elevated temperature, 30^35‡C, for optimal kinase activ-
ity. These ¢ndings are in contrast to the optimal conditions
for mammalian ERK (which uses 10 mM MgCl2, pH 7.4 or 8,
50^100 WM ATP, and 30‡C) [42,43], or S. cerevisiae FUS3
(which uses 20 mM MgCl2, pH 7.4, 20 WM ATP, and 30‡C)
[5]. Elevated temperature and acidic pH are conditions which
P. carinii encounters within the infected host during pneumo-
nia, where the alveolar environment becomes more acidic in
the setting of pneumonia, and fever is part of the host re-
sponse to infection.
Di¡erential expression and/or activity of MAPK molecules
has been noted in pathogenic organisms [44^47]. We examined
separated preparations of P. carinii trophic forms and cysts
for PCM mRNA expression and kinase activity to determine
if this were the case in P. carinii. What is the role of P. carinii
PCM in regulating the life cycle of P. carinii? Although this
will require the ability to isolate pure life cycle stages of the
organism and maintain them in culture, which is currently not
possible, our experimental data implicate a role for PCM in
life cycle transition of P. carinii. Our observation of enhanced
PCM functional kinase activity in the trophic forms compared
to the cysts suggests that the trophic forms utilize PCM. We
cannot conclusively exclude that the techniques for cell prep-
arations of trophic forms and cysts a¡ect the observed kinase
activity, or that the lack of activity in the cyst may be due to a
lack of a speci¢c stimulus for this pathway within P. carinii ;
however, these observations of di¡erential expression or ac-
tivity of signaling molecules have also been recognized in the
life cycle stages of other pathogens. For example, the growth-
regulating MAPK Pf-Map2 from the protozoan parasite Plas-
modium falciparum is expressed only in the gametocyte life
cycle stage, which is formed by sexual di¡erentiation of mer-
ozoites after invasion of the red blood cell. Further, the au-
thors speculate that the kinase activity of the gametocyte
MAPK keeps the gametocyte mitotic cell cycle arrested while
in the blood of the human host, and that the cell cycle block is
relieved when the parasites are transferred back to a mosquito
[22]. Another example comes from the protozoan parasite
Leishmania mexicana, which has two major life cycle forms,
the promastigotes which live in insects and the amastigotes
which replicate in mammalian macrophages. Although not
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implicated in life cycle transition, the LMPK MAPK is essen-
tial for the amastigote survival in an infected host. LMPK
mRNA is found in both promastigotes and amastigotes, but
LMPK kinase activity is only found in amastigotes. Deletion
of LMPK in these organisms results in the parasites’ inability
to grow as amastigotes and thus a loss of infectivity [23]. If
PCM is used for life cycle transition, ¢nding activated PCM in
trophic forms makes sense, since following conjugation the
stimulus and requirement for an activated PCM would not
be needed in cysts. Within Giardia lamblia, a protozoan para-
site which can be cultured and manipulated, MAPK molecules
play a critical role in the trophozoite di¡erentiation into cysts
under conditions of nutrient deprivation [24]. Once the pro-
cess of encystation occurs, MAPK activity becomes attenu-
ated in these organisms and reaches its lowest catalytic activ-
ity 24 h after the trophozoites are stimulated to transform into
cysts, which correlates with the maximum number of cysts
identi¢ed in the culture [24]. Unfortunately, the ability to
transform P. carinii with plasmid DNA or to disrupt its genes
has not yet been perfected, and the inability to culture
P. carinii makes analogous studies currently impossible. We
believe, however, that our observation of increased PCM
kinase activity in the P. carinii trophic forms, combined
with PCM functional complementation of the pheromone sig-
naling MAPK pathway in yeast, suggests that PCM has a role
in regulating the life cycle transition in P. carinii.
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